Several publications document the occurrence of symptoms that persist or occur late. The identification of the observed clinical manifestations and their clinical and paraclinical description are essential to better understand the natural evolution of COVID-19, to clarify the pathophysiological mechanism of these possible late manifestations, and to identify potential management options for patients. Since this type of event is infrequent, a large-scale national multicenter cohort study focusing on symptomatic patients is needed.
Several publications document the occurrence of symptoms that persist or occur late, more
than 3 weeks after the first clinical manifestations of an SARS-COV2 infection. These
manifestations may be related to thromboembolic or inflammatory complications,
superinfections, or other mechanisms not yet well understood, including potentially related
to the persistence of SARS-COV2. The identification of the observed clinical manifestations
and their clinical and paraclinical description are essential to better understand the
natural evolution of COVID-19, to clarify the pathophysiological mechanism of these possible
late manifestations, and to identify potential management options for patients.
Since this type of event is infrequent, a large-scale national multicenter cohort study
focusing on symptomatic patients is needed. In parallel, the prevalence of the main symptoms
observed more than 3 weeks after the onset of a COVID-19 will be estimated through
partnerships with existing cohort studies in the general population or in the population
followed for COVID-19, still symptomatic or not at 3 weeks of infection.
Longitudinal implementation of bio-libraries will allow this cohort to also constitute a
bridge between clinicians and researchers.
Other: Questionnaire
Quality of life and chronic disease impact scales will be completed at inclusion and follow-up visits.
Other: Biocollection
Total serum, plasma samples will be collected
Other: Follow-up visit
All patients will make an inclusion visit (IV), then a clinical follow-up will be organized for the study at M4, M6, M12 from the day of the onset of the 1st symptoms of COVID.
Inclusion Criteria:
- History of symptomatic CoV-2-SARS infection as defined by :
o Positive RT-PCR SARS-CoV-2 RT-PCR result OR positive SARS-CoV-2 serology
o Associated with at least one event : x Anosmia occurring after February 2020 x OR
COVID 19 evocative scanner x OR ≥ 2 contemporary symptoms of the virological sample
from: asthenia, cough, dyspnea, fever, myalgia, dysgeusia, diarrhea AND not present
prior to diagnosis
- AND persistence of at least one symptom present in the first 3 weeks of a COVID-19,
more than 8 weeks away from the first symptoms of COVID-19. OR late onset of at least
one new symptom a minimum of 3 weeks and a maximum of 6 months after the first
symptoms of a CoV-2 SARS infection.
- First symptoms less than 6 months old on the day of inclusion
- To benefit from a State Health Insurance or Medical Aid plan
- Have signed an informed consent for inclusion.
Exclusion Criteria:
- Minor patient
- Patient under protection of justice
- Patient who required intensive care management :
- more than 5 days
- OR requiring orotracheal intubation
- OR having required high flow ventilation (optiflow)
Ch Auxerre
Auxerre, France
CHU Caen
Caen, France
CHRU Lille
Lille, France
CH Melun Marc Jacquet
Melun, France
CH Sud Seine et Marne
Nemours, France
AP-HP Hôpital Hôtel-Dieu
Paris, France
CHU de Saint-Etienne
Saint-Priest-en-Jarez, France
CH Tourcoing
Tourcoing, France
CHRU Tours
Tours, France
CHRU Nancy
Vandœuvre-lès-Nancy, France
Centre Hospitalier Bretagne Atlantique
Vannes, France
CH André Rosemon de Cayenne
Cayenne, French Guiana
Olivier ROBINEAU, MD PhD
0320694949
orobineau@ch-tourcoing.fr
Solange TREHOUX, PhD
0320694280
strehoux@ch-tourcoing.fr
Olivier ROBINEAU, MD PhD, Principal Investigator
CH Tourcoing